OncoMatch/Clinical Trials/NCT04712851
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Is NCT04712851 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Pembrolizumab for cervical intraepithelial neoplasia.
Treatment: Pembrolizumab — This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Disease stage
Grade: 23 (cin)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137)
Cannot have received: systemic therapy
Exception: within the prior 4 weeks prior to allocation
Has received prior systemic therapy for CIN including investigational agents within the prior 4 weeks prior to allocation
Cannot have received: radiotherapy
Exception: within 2 weeks of start of study intervention; 1-week washout permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-central nervous system (CNS) disease
Has received prior radiotherapy within 2 weeks of start of study intervention
Lab requirements
Blood counts
all baseline laboratory assessments in the normal range
Kidney function
all baseline laboratory assessments in the normal range
Liver function
all baseline laboratory assessments in the normal range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California at Los Angeles / Jonsson Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04712851 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy, systemic therapy, radiotherapy disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify